AMAG Pharmaceuticals, Inc. faces Investor Investigation
An investigation for investors in NASDAQ-AMAG shares over potential violations of securities laws by AMAG Pharmaceuticals, Inc. was announced and NASDAQ-AMAG stockholders should contact the Shareholders Foundation at email@example.com
If you are a current long-term investor in shares of AMAG Pharmaceuticals, Inc. , you have certain options and you should contact the Shareholders Foundation at firstname.lastname@example.org (mailto:mail@
The investigation by a law firm concerns whether AMAG Pharmaceuticals, Inc and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On December 21, 2012, AMAG Pharmaceuticals, Inc submitted to the U.S. Food and Drug Administration (the "FDA") a supplemental New Drug Application (the "sNDA") under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Feraheme (ferumoxytol)
On May 21, 2013, AMAG Pharmaceuticals, Incannounced that it has been made aware by Takeda Pharma AG, the exclusive product distributor of ferumoxytol in Switzerland, that it is recalling one specific batch of Rienso® (ferumoxytol)
On September 23, 2013, the Company received a notification from the FDA stating that, as part of its ongoing review of the Company's sNDA, the FDA has identified deficiencies that preclude discussion of labeling and postmarketing requirements/
Shares of AMAG Pharmaceuticals, Inc declined from $26.87 per share on September 24, 2013, to $19.05 per share on Oct. 15, 2013.
Those who purchased shares of AMAG Pharmaceuticals, Inc. , have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 - 1554.
Shareholders Foundation, Inc.